|
|
|
20.06.25 - 01:03
|
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to one new non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan....
|
|
|
|
|
|
|
02.06.25 - 22:33
|
Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes (GlobeNewswire EN)
|
|
|
MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025....
|
|
|
|
|
|
|
14.05.25 - 14:33
|
Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month (GlobeNewswire EN)
|
|
|
MALVERN, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, is proud to launch the first National TMS Therapy Awareness Day. The event will take place each year on May 14 during May's Mental Health Awareness Month. This day is dedicated to raising awareness of transcranial magnetic stimulation (TMS) as a proven, non-drug treatment option for individuals living with major depressive disorder (MDD), depression with anxiety, and OCD, especially those who have not found relief through antidepressants....
|
|
|
|
|
06.05.25 - 14:09
|
Sensydia Appoints Rusty Page as President and Chief Operating Officer to Support Growth and Commercialization of the Cardiac Performance System (CPS™) (Business Wire)
|
|
|
– Industry veteran strengthens Sensydia's leadership team as company advances toward FDA submission –
LOS ANGELES--(BUSINESS WIRE)--Sensydia, a medical technology company advancing non-invasive cardiac assessment, today announced the appointment of Rusty Page as President and Chief Operating Officer. Page joins Sensydia from publicly traded Neuronetics, Inc., where he served as SVP, Chief Information & Operations Officer. He brings more than two decades of senior leadership experience in the medical device and diagnostics industry.
At Sensydia, Mr. Page will have broad responsibility for operations, quality, IT, and business infrastructure as the company prepares for regulatory submission and commercial launch of its non-invasive Cardiac Performance System (CPS™).
“Rusty's track record guiding early-stage medical device companies from development through product launch and commercialization makes him an ideal addition to Sensydia's leadership team,” said Anthony Arnold, CEO of Sensydia. “Hi...
|
|
|
|
|
06.05.25 - 13:12
|
Neuronetics Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire EN)
|
|
|
MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025....
|
|
|
05.05.25 - 22:33
|
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 4,500 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company....
|
|
|
|
|
27.03.25 - 21:33
|
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire EN)
|
|
|
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. Following the Company's press release on March 4, 2025 initially issuing the Company's fourth quarter and full year 2024 financial results (the “Initial Release”) and in connection with finalizing the audited financial statements for the fiscal year ending December 31, 2024, certain non-cash revisions were made to the financial statements related to the Company's acquisition of Greenbrook TMS Inc. (“Greenbrook”) and the shares outstanding in the fourth quarter of 2024. These accounting updates resulted in, among other things:...
|
|
|
|
|
|
|
|
|
|
|
04.03.25 - 13:12
|
Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire EN)
|
|
|
MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2024....
|
|
|
03.03.25 - 22:33
|
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 24,750 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
